Adverse effects of antiepileptic drugs: a brief overview of important issues

被引:84
作者
Cramer, Joyce A. [1 ,2 ]
Mintzer, Scott [3 ]
Wheless, James [4 ]
Mattson, Richard H. [1 ]
机构
[1] Yale Univ, Sch Med, New Haven, CT USA
[2] Epilepsy Therapy Project, Houston, TX USA
[3] Thomas Jefferson Univ, Philadelphia, PA 19107 USA
[4] Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA
关键词
adverse effect; antiepileptic drug; central nervous system; CNS; hypersensitivity; medical; psychiatric; psychological; tolerance; CLINICAL-TRIALS; EPILEPSY; CHILDREN; ADULTS; PHENYTOIN; LEVETIRACETAM; CARBAMAZEPINE; TOLERABILITY; LAMOTRIGINE; MEDICATIONS;
D O I
10.1586/ERN.10.71
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
All medications have some adverse effects, ranging from mild to acute and serious or chronic. Antiepileptic drugs (AEDs) differ in the type and severity of adverse effects, mostly during initiation and early treatment. Some concerns are related to pharmacodynamic tolerance often affected by the dose and rate of initiation, while other concerns are idiosyncratic responses to the drug (rare and not predictable). Thus, lack of tolerability is a common reason for changing medication, quantified in studies as treatment retention. Although adverse effects can occur with all AEDs, and CNS effects are most prevalent, selected effects are hallmarks of specific drugs. The failure of an AED regimen may be the result of unacceptable adverse effects (intolerance), inadequate seizure control (inefficacy) or a combination of both. Although some diminution in adverse effects is typical when a drug is used in monotherapy, the potential for most issues remains if they are dose-related or idiosyncratic. This article describes three categories of prevalent adverse effects (CNS, behavioral and general medical issues) comparing profiles of second- and third-generation AEDs.
引用
收藏
页码:885 / 891
页数:7
相关论文
共 45 条
[1]   Children versus adults: Pharmacokinetic and adverse-effect differences [J].
Anderson, GD .
EPILEPSIA, 2002, 43 :53-59
[2]   Comparison and predictors of rash associated with 15 antiepileptic drugs [J].
Arif, H. ;
Buchsbaum, R. ;
Weintraub, D. ;
Koyfman, S. ;
Salas-Humara, C. ;
Bazil, C. W. ;
Resor, S. R., Jr. ;
Hirsch, L. J. .
NEUROLOGY, 2007, 68 (20) :1701-1709
[3]   Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: The evidence report [J].
Ben-Menachem, Elinor .
EPILEPSIA, 2007, 48 :42-45
[4]  
Besag Frank M C, 2004, Expert Opin Drug Saf, V3, P1
[5]  
Biton V, 2001, ANN PHARMACOTHER, V35, P173
[6]  
BLUMER D, 1995, J NEUROPSYCH CLIN N, V7, P445
[7]   The impact of side effects on long-term retention in three new antiepileptic drugs [J].
Bootsma, Hans P. ;
Ricker, Lukas ;
Hekster, Yechiel A. ;
Hulsman, Jacques ;
Lambrechts, Danielle ;
Majoie, Marian ;
Schellekens, Ad ;
de Krom, Marc ;
Aldenkamp, Albert P. .
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2009, 18 (05) :327-331
[8]   Monitoring for adverse effects of antiepileptic drugs [J].
Camfield, Peter ;
Camfield, Carol .
EPILEPSIA, 2006, 47 :31-34
[9]   New Testing Approach in HLA Genotyping Helps Overcome Barriers in Effective Clinical Practice [J].
Cheng, Suk-Hang ;
Kwan, Patrick ;
Ng, Ho-Keung ;
Ng, Margaret H. -L. .
CLINICAL CHEMISTRY, 2009, 55 (08) :1568-1572
[10]   Differentiating anxiety and depression symptoms in patients with partial epilepsy [J].
Cramer, JA ;
Brandenburg, N ;
Xu, X .
EPILEPSY & BEHAVIOR, 2005, 6 (04) :563-569